← Leaderboards
Panagiotis Ntziachristos
New York University School Of Medicine
$1,562,520
Attributed
$1,562,520
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $364.1K · FY2014–21$500K$375K$250K$125K$0
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$1,562,520 · 3
By mechanism
R00$747,000 · 1
R01$725,520 · 1
K99$90,000 · 1
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Iannis Aifantis$31,581,069
- Susan Ruth Schwab$12,737,775
- Hyunsoo Chung$54,538
Others in their field
Top investigators on “High Risk”
- Lawrence Corey · Fred Hutchinson Cancer Center$561,333,990
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$424,554,257
- Wafaa M. El-Sadr · Columbia University Health Sciences$337,188,987
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$303,724,352
Research focus
High RiskMolecularEnvironmentGrowthMalignant StateMalignant NeoplasmsChromatinDiagnosisEpigenetic ProcessGene ExpressionInhibitor/AntagonistIn VivoLeukemiaMaintenanceAcute T Cell LeukemiaChildComplexCoupledAnimalsChemotherapyCellsFutureHistonesMouse Model
Grant awards (6)
Therapeutic targeting of demethylation-deubiquitination axis in acute leukemia$364,095
R01 · FY2021 · CA · contact PI
Therapeutic targeting of demethylation-deubiquitination axis in acute leukemia$361,425
R01 · FY2020 · CA · contact PI
Exploring a new therapeutic approach through targeting epigenetic enzymes in ALL$249,000
R00 · FY2017 · CA · contact PI
Exploring a new therapeutic approach through targeting epigenetic enzymes in ALL$249,000
R00 · FY2016 · CA · contact PI
Exploring a new therapeutic approach through targeting epigenetic enzymes in ALL$249,000
R00 · FY2015 · CA · contact PI
Exploring a new therapeutic approach through targeting epigenetic enzymes in ALL$90,000
K99 · FY2014 · CA · contact PI